Abstract Library

#3871 A phase 2, randomized, parallel-group study to evaluate the safety, pharmacokinetics, and dose response of paltusotine treatment in patients with carcinoid syndrome

Introduction: While long-acting somatostatin receptor ligands (SRLs) are mainstay treatments for carcinoid syndrome (CS), symptom relief at labelled doses is inadequate for many patients. Paltusotine is a novel oral, nonpeptide, selective somatostatin receptor type 2 agonist. In patients with acromegaly, paltusotine maintains plasma IGF-1 levels in patients switching from long-acting SRLs. Paltusotine was well tolerated in phase 2 acromegaly studies.

Conference:

Presenting Author:

Authors: Chauhan A, Shaheen S, Usiskin K, Odueyungbo A, Mui C,

Keywords: Paltusotine, Phase 2 trial, Somatostatin receptor agonist, Safety, Pharmacokinetics, Carcinoid syndrome,

#3305 177Lu-Dotatate efficacy and safety in functioning neuroendocrine tumors: A joint analysis of phase 2 prospective clinical trials

Introduction: Neuroendocrine tumors are a rare neoplasia. At least 25% of patients (pts) with advanced disease may have functioning neuroendocrine tumors (F-NETs) that can secrete bioactive peptides that can lead to specific symptoms like diarrhea that can be debilitating and life-threatening.Although symptom relief is available with somatostatin analogs (SSA), the disease eventually becomes refractory to SSA,leaving no proven treatment options

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Bongiovanni A

Authors: Bongiovanni A, Nicolini S, Ibrahim T, Foca F, Sansovini M,

Keywords: neuroendocrine tumor, carcinoid syndrome, neuroendocrine neoplasia, PRRT, insulinoma, 177Lu-Dotatate, functioning tumor,

#1873 Meta-Analysis of Liver Resection versus Nonsurgical Treatments for Pancreatic Neuroendocrine Tumors with Liver Metastases

Introduction: Available data comparing the efficacy of different treatment regiments are rarely found. No meta-analyses have compared live resection with other nonsurgical treatments in resectable liver metastases from pNETs.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Yuan C,

Keywords: meta-analysis, pancreatic neuroendocrine tumors (p-NETs) , liver metastasis, liver resection,

#1811 Safety and Tolerability of Lanreotide Autogel/Depot (LAN) in Patients (pts) with Neuroendocrine Tumours (NETs): Pooled Analysis of Clinical Studies

Introduction: Two randomized double-blind (DB) trials demonstrated the efficacy of LAN 120mg/4weeks vs placebo in NETs: PFS improved in metastatic non-functioning intestinal/pancreatic NETs (CLARINET); less rescue medication used for carcinoid syndrome (CS) (ELECT).

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Phan A, Wolin E, Fisher G, Ruszniewski P, Pavel M,

Keywords: Lanreotide, safety,

#1602 Systematic Review of Resecting Primary Tumor in MNETs Patients with Unresectable Liver Metastases

Introduction: Treatment for midgut neuroendocrine tumors (MNETS) with unresectable liver metastasis has long been a controversial issue.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Zhao H

Authors: Guo J, Bi X, Zhou J, Li Z, Huang Z,

Keywords: midgut neuroendocrine tumor, liver metastasis, primary tumor resection,